MedPath

Safety of Enoxaparin versus unfractioned heparin in patients undergoing percutaneous coronary intervention using drug eluting stents: A pilot study

Phase 3
Conditions
Coronary Artery Disease.
Chronic ischaemic heart disease
Registration Number
IRCT138710101525N1
Lead Sponsor
Vice-chanceller for Research Affairs, Shiraz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
200
Inclusion Criteria

Patients with atherosclerotic coronary artery disease (chronic stable angina or acute coronary syndromes) were included if they were candidate for PCI as a result of uncontrolled anginal pain, unresponsive to the maximum dose of nitrates or incidence of adverse drug reactions in which it was impossible to continue medical treatment, Patients with clinical sign of heart failure and ischemic involvement of a relatively large segment of myocardium
Exclusion criteria: Age 75 years or older, presence of renal failure defined as creatinine clearance of 30 ml/min and over,creatinine=2.5 mg/dl in male and creatinine=2.0 mg/dl in female participants, use of bare-metal stents, presence of primary PCI, receiving heparin or LMWH before randomization, unacceptable prothrombin time (PT) or platelet count, presence of platelet functional disorders or coagulopathies, or hypercoagulopathy syndromes.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The incidence of minor bleedings. Timepoint: During the first 24 hours following the index PCI. Method of measurement: by observation.;The incidence of major bleedings. Timepoint: during the first 24 hours following the index PCI. Method of measurement: Major bleeding was defined as clinically overt bleeding causing a decrease in hemoglobin = 3 g/dl requiring transfusion of packed red cells or whole blood, bleedings which require surgical intervention to stop bleeding at the femoral sheath insertion site, intracranial bleeding, and retroperitoneal bleeding.
Secondary Outcome Measures
NameTimeMethod
The incidence of in-stent acute coronary thrombosis. Timepoint: during 24 hours after PCI. Method of measurement: by Observation.
© Copyright 2025. All Rights Reserved by MedPath